Rare subtypes of adenocarcinoma of the lung

References

• WHO. Histological typing of Lung and Pleural Tumors (3rd edition). Travis WD, Colby TV, Corrin B et al. (Eds). Springer-Verlig Berlin, Germany (1999).
   Google Scholar
• Travis WD, Brambilla E, Noguchi M et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J. Thorac. Oncol.6, 244–285 (2011).
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med.350, 2129–2139 (2004).
   PubMed Web of Science ®Google Scholar
• Finberg KE, Sequist LV, Joshi VA et al. Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar carcinoma. J. Mol. Diagn.9, 320–326 (2007).
   PubMedGoogle Scholar
• Sakuma Y, Matsukuma S, Yoshihara M et al. Distinctive evolution of nonmucinous and mucinous bronchioloalveolar carcinoma in EGFR and KRAS gene-mutation analyses for Japanese lung adenocarcinomas. Confirmation of the correlations with histologic subtypes and gene mutations. Am. J. Clin. Pathol.128, 100–108 (2007).
   PubMedGoogle Scholar
• Rossi GR, Murer B, Cavazza A et al. Primary mucinous (so-called colloid) carcinomas of the lung: a clinicopathologic and immunohistochemical study with special reference to CDX2 homeobox gene and MUC2 expression. Am. J. Surg. Pathol.28, 442–452 (2004).
   PubMed Web of Science ®Google Scholar
• Takao M, Takagi T, Suzuki H et al. Resection of mucinous adenocarcinoma presenting with intractable bronchorrhea. J. Thorac. Oncol.5, 576–578 (2010).
   PubMedGoogle Scholar
• Sato S, Koike T, Yamato Y et al. Resected well-differentiated fetal pulmonary adenocarcinoma and summary of 25 cases in Japan. Jpn. J. Thorac. Cardiovas.54, 539–542 (2006).
   PubMedGoogle Scholar
• Koss MN, Hochholzer L, O’Leary T. Pulmonary blastomas. Cancer67, 2368–2381(1991).
   PubMed Web of Science ®Google Scholar
• Sekine S, Shibata T, Matsuno Y et al. β-catenin mutations in pulmonary blastomas: association with morule formation. J. Pathol.200, 214–221 (2003).
   PubMedGoogle Scholar
• Yousem SA. Pulmonary intestinal-type adenocarcinoma does not show enteric differentiation by immunohistochemical study. Modern Pathol.18, 816–821 (2005).
   PubMedGoogle Scholar
• Inamura K, Satah Y, Okumura S et al. Pulmonary adenocarcinomas with enteric differentiation. Histologic and immunohistochemical characteristics compared with metastatic colorectal cancers and usual pulmonary adenocarcinomas. Am. J. Surg. Pathol.29, 660–665 (2005).
   PubMed Web of Science ®Google Scholar
• Li HC, Schmidt L, Greenson JK et al. Primary pulmonary adenocarcinoma with intestinal differentiation mimicking metastatic colorectal carcinoma. Am. J. Clin. Pathol.131, 129–133 (2009).
   PubMedGoogle Scholar
• Katzenstein AA, Prioleau PG, Askin FB. The histologic spectrum and significance of clear-cell change in lung carcinoma. Cancer45, 943–947 (1980).
   PubMed Web of Science ®Google Scholar
• Rodig SJ, Mino-Kenudson M, Dacic S et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin. Cancer Res.15, 5216–5223 (2009).
   PubMed Web of Science ®Google Scholar
• Shaw AT, Yeap BY, Mino-Kneudson M et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4–ALK. J. Clin. Oncol.27, 4247– 4253 (2009).
   PubMed Web of Science ®Google Scholar
• Yoshida A, Tsuta K, Watanabe SI et al. Frequent ALK rearrangement and TTF-1/p63 co-expression in lung adenocarcinoma with signet-ring cell component. Lung Cancer72, 309–351 (2011).
   PubMed Web of Science ®Google Scholar
• Ou S-HI, Ziogas A, Zell JA. Primary signet-ring carcinoma (SRC) of the lung. A population-based epidemiologic study of 262 cases with comparison to adenocarcinoma of the lung. J. Thorac. Oncol.5, 420–427 (2010).
   PubMed Web of Science ®Google Scholar
• Sun Y, Ren Y, Fang Z et al. Lung adenocarcinoma from East Asia never-smokers is a disease largely defined by targetable oncogenic mutant kinases. J. Clin. Oncol.28, 4616–4620 (2010).
   PubMed Web of Science ®Google Scholar
• Marchetti A, Felicioni L, Malatesta S et al. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J. Clin. Oncol.29, 3574–3579 (2011).
   PubMed Web of Science ®Google Scholar
• Rikova K, Guo A, Zeng Q et al. Global survey of phosphotyrosine signaling identified oncogenic kinases in lung cancer. Cell131, 1190–1203 (2007).
   PubMed Web of Science ®Google Scholar
• Soda M, Choi YL, Enomoto M et al. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer. Nature448, 561–566 (2007).
   PubMed Web of Science ®Google Scholar
• Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol.12, 175–180 (2011).
   PubMed Web of Science ®Google Scholar
• Kwak EL, Bang Y-J, Camidge DR et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med.363, 1693–1703 (2010).
   PubMed Web of Science ®Google Scholar
• Maemondo M, Inoue A, Kobayashi K et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med.362, 2380–2388 (2010).
   PubMed Web of Science ®Google Scholar
• Sequist LV, Waltman BA, Dias-Santagata D et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med.3, 75ra26 (2011).
   PubMed Web of Science ®Google Scholar
• Maheswaran S, Sequist LV, Nagrath S et al. Detection of mutations in EGFR circulating lung-cancer cells. N. Engl. J. Med.359, 366–377 (2008).
   PubMed Web of Science ®Google Scholar